Integrated therapeutic strategies for anaplastic thyroid carcinoma

Tumori

Volumn 89, Issue 5, 2003, Pages 544-546

  Buzzoni, Roberto ^a   Catena, Laura ^a   Cortinovis, Diego ^a   Dognini, Giuseppina ^a   Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anaplastic thyroid carcinoma; Chemotherapy; Integrated radiotherapeutic strategies

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MANUMYCIN; OSTEOGENIC PROTEIN 1; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RIBONUCLEASE;

ANAPLASTIC CARCINOMA; ANAPLASTIC THYROID CARCINOMA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RADIATION DOSE; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0347824358     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900518     Document Type: Article

References (22)

1. Gilliland FD, Hunt WC, Morris DM, Key CR: Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program 1973-1991. Cancer, 79: 564-573, 1997.
2. Ain KB: Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol, 16: 64-69, 1999.
3. Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennevall J, Blomgren H, Grimelius L, Lundell G, Walling G: Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. Word J Surg, 22: 725-730, 1998.
4. McIver B, Hay ID, Giuffrida D, Dvorak CE, Grant CS, Thompson GB, van Heerden MD, Goellner JR: Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery, 130: 1028-1034, 2001.
5. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A: Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg, 25: 617-622, 2001.
6. Kobayashi A, Asakawa H, Umeshita K, Takeda T, Maruyana H, Matsuzuka F, Monden M: Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck, 18: 36-41, 1996.
7. Sugino K, Ito K, Mimura T, Nagahama M, Fukunari N, Kubo A, Iwasaki H, Ito K: The important role of operations in the management of anaplastic thyroid carcinoma. A clinicopathologic study of 121 cases. Surgery, 131: 245-248, 2002.
8. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goeffert H, Samaan MA: Anaplastic carcinoma of the thyroid. Cancer, 66: 321-330, 1990.
9. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivery JM, Duh QY, Clark OH: Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer, 23: 1252-1261, 2001.
10. Junior EJ, Paul J, Redd NS: Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol, 18: 83-88, 1992.
11. Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A: Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol, 27: 260-264, 2001.
12. Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ: The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol, 9: 57-64, 2002.
13. Heron DE, Karinpour S, Grigsby W: Anaplastic thyroid carcinoma. Am J Clin Oncol, 25: 442-446, 2002.
14. Kim J, Leeper RD: Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer, 60: 2372-2375, 1987.
15. Pasieka JL: Anaplastic thyroid cancer. Curr Opin Oncol, 15: 78-83, 2003.
16. Ain KB, Egorin MJ, DeSimone PA: Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Thyroid, 10: 587-594, 2000.
17. Xu G, Pan J, Martin C, Yeung J: Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metabol, 86: 1769-1777, 2001.
18. Voigt W, Bulankin T, Muller C, Schoeber A, Grothey A, Hoang-Vu, Schmoll HJ: Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res, 6: 2087-2093, 2000.
19. Tennvall J, Lundell, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, Hjelm Skog AL, Wallin G: Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyper-fractionated radiotherapy and surgery. Br J Cancer, 86: 1848-1853, 2002.
20. Nagayama Y, Tokoi H, Takeda K, Hasegawa M, Nishihara E, Namba H, Yamashita S, Niwa M: Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab, 85: 4081-4086, 2000.
21. Franzen A, Heldin N: BMP-7 induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21CIP1 and p27KIP1. Biochem Biophys Res Commun, 285: 773-781, 2001.
22. Kotchetkov R, Cinati J, Krivtchik A, Vogel J, Matousek J, Pouckova P, Kornhuber B, Schwabe D, Cinatl J: Selective activity of BS-Rnase against anaplastic thyroid cancer. Anticancer Res, 21: 1035-1042, 2001.